Antithrombotic Therapy

Anticoagulant Medications

The American College of Chest Physicians recommends heparin for initial treatment of venous thromboembolism (VTE) 1
Low-molecular-weight heparin (LMWH) is generally preferred over intravenous unfractionated heparin (IV UFH) due to its better safety profile 1
Vitamin K antagonists (VKAs) such as warfarin inhibit the synthesis of vitamin K-dependent clotting factors (II, VII, IX, and X) and are effective for long-term management of thrombotic conditions including atrial fibrillation, venous thromboembolism, and mechanical heart valves 2
The American Heart Association recommends regular INR monitoring to maintain therapeutic anticoagulation with VKAs, with a target INR of 2.0-3.0 2

Aspirin is an antiplatelet agent that inhibits platelet aggregation by irreversibly blocking cyclooxygenase-1 (COX-1) and preventing thromboxane A2 production, and is recommended for prevention of atherothrombotic events in patients with atherosclerotic disease 5
The American College of Cardiology recommends aspirin in combination with other antithrombotic agents in specific clinical scenarios, though this increases bleeding risk 6

The choice between antithrombotic agents depends on the specific clinical indication, patient characteristics, and bleeding risk, with combination therapy with multiple antithrombotic agents significantly increasing bleeding risk by 40-50% 1
Regular INR monitoring is essential for patients on VKAs to maintain therapeutic anticoagulation and prevent both thrombotic and bleeding complications 2

Anticoagulants (heparin and vitamin K antagonists) target the coagulation cascade, while antiplatelet drugs (aspirin) inhibit platelet activation, and in some clinical scenarios, dual anti-thrombotic pathway inhibition may provide additional benefit but increases bleeding risk 6